Cargando…
The Parsortix™ Cell Separation System—A versatile liquid biopsy platform
Cancer cells from solid tumors can enter the circulatory system and survive to subsequently form distant metastases. The CellSearch® system (Menarini‐Silicon Biosystems, Huntingdon Valley, PA) was the first, FDA‐cleared system that provided a reliable tool for the investigation of circulating tumor...
Autores principales: | Miller, M. Craig, Robinson, Peggy S., Wagner, Christopher, O'Shannessy, Daniel J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6586069/ https://www.ncbi.nlm.nih.gov/pubmed/30107082 http://dx.doi.org/10.1002/cyto.a.23571 |
Ejemplares similares
-
Centrifugation affects the purity of liquid biopsy‐based tumor biomarkers
por: Rikkert, Linda G., et al.
Publicado: (2018) -
Blood‐based biopsies—clinical utility beyond circulating tumor cells
por: Tang, Cha‐Mei, et al.
Publicado: (2018) -
The RareCyte® platform for next‐generation analysis of circulating tumor cells
por: Kaldjian, Eric P., et al.
Publicado: (2018) -
How to Agree on a CTC: Evaluating the Consensus in Circulating Tumor Cell Scoring
por: Zeune, Leonie L., et al.
Publicado: (2018) -
Automated rare single cell picking with the ALS cellcelector™
por: Nelep, Constantin, et al.
Publicado: (2018)